An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Glomerulonephritis; Membranous glomerulonephritis
- Focus Registrational; Therapeutic Use
- Acronyms VALE
- Sponsors Apellis Pharmaceuticals
Most Recent Events
- 07 Mar 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 14 Apr 2023 Status changed from recruiting to not yet recruiting.
- 28 Feb 2023 New trial record